Blog Posts

Giulio Francolini: QoL data from DART trial

Giulio Francolini/urotoday.com

May 4, 2025, 12:33

Giulio Francolini: QoL data from DART trial

Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:

“QoL data from DART trial (SBRT+/- darolutamide in oligorec. pCa).

Global health and most QoL subdomains remained stable in both arms over the 24-week period.

More fatigue and hormonal treatment-related symptoms were observed in the SBRT and DARO arm, ESTRO.”

The post presents updated findings from the DART trial, indicating stable quality of life across both study arms over 24 weeks.

However, patients receiving both SBRT and darolutamide experienced increased fatigue and hormonal symptoms.

Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.

cancer Careggi University Hospital darolutamide DART trial ESTRO fight against cancer Giulio Francolini Global fight against cancer global health OncoDaily Oncology QoL data Radiation Oncologist SBRT

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth